The legal back and forth between Dexcom (NSDQ:DXCM) and AgaMatrix over the companies’ continuous glucose monitoring IP dates back to March of 2016, when AgaMatrix launched a patent infringement lawsuit against the San Diego, Calif.-based manufacturer in the U.S. District Court of Oregon.
Later that year, Dexcom filed for inter parters review with the Patent Trial and Appeal Board, hoping that the board would find that the patents cited in AgaMatrix’s lawsuit were invalid under patent law. But today, the PTAB ruled that AgaMatrix’s patents are valid and that Dexcom failed to prove that the claims were unpatentable due to obviousness.
Get the full story at our sister site, Drug Delivery Business News.
